Lurie Ido, Yang Yu-Xiao, Haynes Kevin, Mamtani Ronac, Boursi Ben
Tel-Aviv University, Tel-Aviv, Israel.
Shalvata Mental Health Center, Hod Hasharon, Israel.
J Clin Psychiatry. 2015 Nov;76(11):1522-8. doi: 10.4088/JCP.15m09961.
Changes in the microbiota (dysbiosis) were suggested to increase the risk of several psychiatric conditions through neurologic, metabolic, and immunologic pathways. Our aim was to assess whether exposure to specific antibiotic groups increases the risk for depression, anxiety, or psychosis.
We conducted 3 nested case-control studies during the years 1995-2013 using a large population-based medical record database from the United Kingdom. The study included 202,974 patients with depression, 14,570 with anxiety, and 2,690 with psychosis and 803,961, 57,862, and 10,644 matched controls, respectively. Cases were defined as individuals aged 15-65 years with any medical Read code for depression, anxiety, or psychosis. Subjects with diagnosis-specific psychotropic prescriptions > 90 days before index date were excluded. For every case, 4 controls were selected using incidence density sampling, matching on age, sex, practice site, calendar time, and duration of follow-up before index date. The primary exposure of interest was therapy with 1 of 7 antibiotic classes > 1 year before index date. Odds ratios (ORs) and 95% CIs were calculated for the association between each psychiatric disorder and exposure to individual classes of antibiotics using conditional logistic regression analysis. The risk was adjusted for obesity, smoking history, alcohol consumption, socioeconomic status, and number of infectious events before diagnosis.
Treatment with a single antibiotic course was associated with higher risk for depression with all antibiotic groups, with an adjusted OR (AOR) of 1.23 for penicillins (95% CI, 1.18-1.29) and 1.25 (95% CI, 1.15-1.35) for quinolones. The risk increased with recurrent antibiotic exposures to 1.40 (95% CI, 1.35-1.46) and 1.56 (95% CI, 1.46-1.65) for 2-5 and > 5 courses of penicillin, respectively. Similar association was observed for anxiety and was most prominent with exposures to penicillins and sulfonamides, with an AOR of 1.17 (95% CI, 1.01-1.36) for a single course of penicillin and 1.44 (95% CI, 1.18-1.75) for > 5 courses. There was no change in risk for psychosis with any antibiotic group. There was a mild increase in the risk of depression and anxiety with a single course of antifungals; however, there was no increase in risk with repeated exposures.
Recurrent antibiotic exposure is associated with increased risk for depression and anxiety but not for psychosis.
微生物群的变化(生态失调)被认为会通过神经、代谢和免疫途径增加患几种精神疾病的风险。我们的目的是评估接触特定抗生素类别是否会增加患抑郁症、焦虑症或精神病的风险。
我们在1995年至2013年期间进行了3项嵌套病例对照研究,使用了来自英国的一个基于人群的大型医疗记录数据库。该研究包括202974例抑郁症患者、14570例焦虑症患者和2690例精神病患者,以及分别与之匹配的803961例、57862例和10644例对照。病例定义为年龄在15至65岁之间且有任何抑郁症、焦虑症或精神病医学读取代码的个体。排除在索引日期前90天以上有特定诊断精神药物处方的受试者。对于每例病例,使用发病密度抽样方法选择4例对照,在年龄、性别、执业地点、日历时间和索引日期前的随访时间方面进行匹配。感兴趣的主要暴露因素是在索引日期前1年以上使用7种抗生素类别中的1种进行治疗。使用条件逻辑回归分析计算每种精神疾病与接触各类抗生素之间关联的比值比(OR)和95%可信区间(CI)。对肥胖、吸烟史、饮酒情况、社会经济地位和诊断前感染事件数量进行风险调整。
使用单一疗程抗生素治疗与所有抗生素类别导致的抑郁症风险升高相关,青霉素的调整后OR(AOR)为1.23(95%CI,1.18 - 1.29),喹诺酮类为1.25(95%CI,1.15 - 1.35)。随着抗生素反复暴露,青霉素2 - 5个疗程和超过5个疗程的风险分别增加到1.40(95%CI,1.35 - 1.46)和1.56(95%CI,1.46 - 1.65)。焦虑症也观察到类似关联,青霉素和磺胺类药物暴露最为显著,青霉素单一疗程的AOR为1.17(95%CI,1.01 - 1.36),超过5个疗程为1.44(95%CI,1.18 - 1.75)。任何抗生素类别与精神病风险均无变化。使用单一疗程抗真菌药物会使抑郁症和焦虑症风险略有增加;然而,反复暴露风险并未增加。
反复接触抗生素与抑郁症和焦虑症风险增加相关,但与精神病风险无关。